New Whitepaper: Origination in the Age of AI–How signal-driven infrastructure is replacing broker-dependent deal flow.Read now↗

PE Firms M&A Firms Commercial Lenders Investment Banks
Deal Origination
End-to-end outreach infrastructure that sources proprietary deal flow.
Data & Research
TAM mapping, data enrichment, custom scraping, and automated research.
Trigger Intelligence (Signals)
Signal-driven deal intelligence delivered to your CRM, Slack, and email.
Resources
Playbooks
Channel-specific outreach playbooks for deal origination.
All research
Comparison posts, methodology, and analysis from the Tentt team.
Reports
Monthly market reports on M&A and private equity activity.
Tools
Free calculators for M&A, lending, and deal analysis.
Whitepaper↗
Origination in the Age of AI.
About
Book an intro call

TaiLin Pharmaceuticals — Acquisitions & M&A Deals

1 deal

Tracking 1 M&A deal by TaiLin Pharmaceuticals.

TaiLin Pharmaceuticals (01011) has completed the acquisition of 58.11% equity in Zhejiang Kangyuan Medical Devices. - 富途牛牛

HealthcareAdd-on

TaiLin Pharmaceuticals→Zhejiang Kangyuan Medical Devices

Mar 25, 2026